✦ LIBER ✦

Cetuximab adds benefit in first-line treatment of metastatic colorectal cancer

Book ID: 120849370
Publisher: Adis International Limited (now part of Wolters Kluwer Health)
Year: 2007
Weight: 133 KB
Volume: &NA;
Category: Article
ISSN: 1173-8324
DOI: 10.2165/00128413-200715710-00030

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

PCN3 Cetuximab for the First-Line Treatm

PCN3 Cetuximab for the First-Line Treatment of Metastatic Colorectal Cancer

✍ Ubago, R.; Castillo, M.A.; Flores, S.; Rodriguez, R.; Beltran, C. 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 70 KB

Cetuximab plus FOLFIRI as a first-line t

Cetuximab plus FOLFIRI as a first-line therapy in metastatic colorectal cancer

✍ Daniel G. Haller 📂 Article 📅 2012 🏛 Frontline Medical Communications, Inc. 🌐 English ⚖ 100 KB

Cetuximab plus FOLFIRI in first-line tre

Cetuximab plus FOLFIRI in first-line treatment of KRAS mutation-negative, EGFR-positive metastatic colorectal cancer

✍ Jame Abraham 📂 Article 📅 2012 🏛 Frontline Medical Communications, Inc. 🌐 English ⚖ 105 KB

Cetuximab effective in treatment-refract

Cetuximab effective in treatment-refractory metastatic colorectal cancer

📂 Article 📅 2006 🏛 Adis International Limited (now part of Wolters Kl ⚖ 133 KB

Fluorouracil, Leucovorin, and Oxaliplati

Fluorouracil, Leucovorin, and Oxaliplatin With and Without Cetuximab in the First-Line Treatment of Metastatic Colorectal Cancer

✍ Bokemeyer, C.; Bondarenko, I.; Makhson, A.; Hartmann, J. T.; Aparicio, J.; de Br 📂 Article 📅 2009 🏛 American Society of Clinical Oncology 🌐 English ⚖ 201 KB

Fluorouracil, Leucovorin, and Oxaliplati

Fluorouracil, Leucovorin, and Oxaliplatin With and Without Cetuximab in the First-Line Treatment of Metastatic Colorectal Cancer

✍ Bokemeyer, C.; Bondarenko, I.; Makhson, A.; Hartmann, J. T.; Aparicio, J.; de Br 📂 Article 📅 2009 🏛 American Society of Clinical Oncology 🌐 English ⚖ 201 KB

## Purpose This randomized study assessed whether the best overall response rate (ORR) of cetuximab combined with oxaliplatin, leucovorin, and fluorouracil (FOLFOX-4) was superior to that of FOLFOX-4 alone as first-line treatment for metastatic colorectal cancer. The influence of KRAS mutation sta